Nathan, S. D., Fernandes, P., Psotka, M., Vitulo, P., Piccari, L., Antoniou, K., . . . Stockbridge, N. (2022). Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.
Citación estilo ChicagoNathan, Steven D., Peter Fernandes, Mitchell Psotka, Patrizio Vitulo, Lucilla Piccari, Katerina Antoniou, Sylvia M. Nikkho, y Norman Stockbridge. Pulmonary Hypertension in Interstitial Lung Disease: Clinical Trial Design and Endpoints: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. 2022.
Cita MLANathan, Steven D., et al. Pulmonary Hypertension in Interstitial Lung Disease: Clinical Trial Design and Endpoints: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. 2022.